@misc{oai:repo.qst.go.jp:00062857,
 author = {Kamada, Tadashi and Imai, Reiko and Tsuji, Hiroshi and Serizawa, Itsuko and Okada, Toru and 鎌田 正 and 今井 礼子 and 辻 比呂志 and 芹澤 慈子 and 岡田 徹},
 month = {Nov},
 note = {Objectives: To evaluate the effectiveness and safety of carbon ion radiotherapy in patients with sacral chorodma and to compare the results of carbon ion radiotherapy with those of surgical series in literature.
Methods: Between 1996 and 2007, 95 patients with sacral chordoma were included in the phase I/II and phase II study of carbon ion radiotherapy for unresectable bone and soft tissue sarcomas. There were sixty-eight males and 27 females. Median age was 66 years (30-85). Eighty-four patients were presented with primary disease and 11 patients with post operative recurrent tumor. Total dose of52.8 to 73.6 GyE was given in 16 fractions over 4 weeks (4 days a week).
Results: All patients completed the planned carbon ion radiotherapy. Median survival time was 42 months (13-112). Overall survival rate at 5 years (86%) in patients with sacral chordoma treated by carbon ion radiotherapy is similar to those in reported data on patients treated by surgical resection with/without adjuvant radiotherapy. Local control rate at 5years (88%) in patients with sacral chordoma treated by carbon ion radiotherapy is better than those in reported data. Median time local failure was 35 months (13-60). Four patients treated with a total dose of 73.6 GyE experienced Grade 3/4 skin/soft tissue complications. No other treatment-related surgical interventions including colostomy or urinary diversion were carried out in this series. Fifteen patients required persistent medication for peripheral neuropathy.
Conclusions: Carbon ion therapy is suggested to be an effective and safe treatment for sacral chordomas, but further experience and longer follow-up are still needed., 14th Annual CTOS Meeting},
 title = {Carbon ion radiotherapy for sacral chordoma},
 year = {2008}
}